A non-randomized, open‐Label, single-dose, parallel group study of pharmacokinetics and safety of bempedoic acid subjects with normal and mildly (Child‐Pugh Class A) and moderately (Child‐Pugh Class B) impaired hepatic function
Latest Information Update: 23 Apr 2021
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions; Pharmacokinetics
- 23 Apr 2021 New trial record
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics